Security key
501575104
Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)
CUSIP: 501575104
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 69,051,239
- Total 13F value
- $3,268,392,680
- Share change
- -1,292,532
- Put/Call ratio
- 161%
- SEC-reported price per share
- $47.33
- Number of holders
- 174
- Value change
- +$183,360
- Number of buys
- 87
- Number of sells
- 79
- Shares outstanding
- 83,129,381
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
174
Top holders
10
KYMR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 501575104
Recent filing periods:
Ownership snapshot
Top reported holders of KYMR - Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PRICE T ROWE ASSOCIATES I...
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
Lead comparable stake: 7.7%
Showing 1-6 of 15 holder rows.
Quick read
PRICE T ROWE ASSOCIATES INC /MD/ leads the comparable SEC ownership view at 7.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PRICE T ROWE ASSOCIATES INC /MD/'s linked filing trail.
Comparable ownership
Top 5
PRICE T ROWE ASSOCIATES INC /MD/
7.7%
BAKER BROS. ADVISORS LP
7.2%
Atlas Venture Life Science Adviso...
6.4%
BVF INC/IL
6.2%
FMR LLC
5.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
7.7%
|
$190,763,000
6,390,658 shares
|
— | 30 Jun 2024 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
7.2%
|
$178,978,451
5,995,928 shares
|
— | 30 Jun 2024 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
6.4%
|
$159,710,097
5,350,422 shares
|
— | 30 Jun 2024 |
| BVF INC/IL |
13F
Company
|
6.2%
|
$154,079,760
5,161,801 shares
|
— | 30 Jun 2024 |
| FMR LLC |
13F
Company
|
5.8%
|
$144,081,174
4,826,840 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
5.8%
|
$143,949,118
4,822,416 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
174
Shares
69,051,239
Rows available
174
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
153
Q3 2024 holders
174
Holder diff
21
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend